|
The drug, aldoxorubicin, was tested in patients with glioblastoma
multiforme (GBM) whose tumors had progressed post surgery as well as
radiation and was successful in preventing further progression and
shrank tumors in several patients.
GBM is the most deadly form of brain cancer and affects more than
12,000 people in the United States annually, the company said.
Aldoxorubicin is an improved version of the chemotherapy agent,
doxorubicin, without causing side effects such as gastrointestinal
disorders and heart muscle damage at higher doses.
The U.S. Food and Drug Administration had in November placed a hold
on enrolling new patients in trials, after one patient died. Cytrx
did not disclose the cause of death at the time.
The drug is also being tested to treat patients with soft tissue
sarcoma, small cell lung cancer and pancreatic cancer.
[to top of second column] |
More detailed data on the trial on patients with brain cancer is
expected in the first half of 2015.
Cytrx shares were at $3.78 in premarket trading on Tuesday. They
closed at $2.85 on the Nasdaq on Monday.
(Reporting by Rosmi Shaji in Bengaluru; Editing by Savio D'Souza)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
